Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

No abstract is available for this paper.

• Publication year

  1985

• Venue

  European Journal of Pharmacology

• Publication date

  1985-10-22

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0014-2999(85)90168-2PMID 3935467
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat

  1985cited by this paper
• Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

  1985cited by this paper
• Neurochemical and Histochemical Characterization of Neurotoxic Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine on Brain Catecholamine Neurones in the Mouse

  1985cited by this paper
• 1-Methyl-4-phenylpyridine (MPP+) is toxic to mesencephalic dopamine neurons in culture.

  1985cited by this paper
• Dopaminergic toxicity after the stereotaxic administration of the 1-methyl-4-phenylpyridinium ion (MPP+) to rats.

  1985cited by this paper
• Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity.

  1985cited by this paper
• 2 – Monoamine oxidase inhibitor antidepressants

  1985cited by this paper
• Pargyline prevents MPTP-induced parkinsonism in primates.

  1984cited by this paper
• Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

  1984cited by this paper
• Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

  1984cited by this paper
• Monoamine oxidase type B inhibitors in the treatment of Parkinson's disease.

  1984cited by this paper
• Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

  1984cited by this paper
• Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

  1984cited by this paper
• Clues to aetiology from a toxin

  1984cited by this paper
• Parkinson's disease: Clues to aetiology from a toxin

  1984cited by this paper
• Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism

  1984cited by this paper
• A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1983cited by this paper
• SELECTIVE ACETYLENIC ‘SUICIDE’ AND REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE TYPES A AND B

  1981cited by this paper
• TYRAMINE ANTAGONISTIC PROPERTIES OF AGN 1135, AN IRREVERSIBLE INHIBITOR OF MONOAMINE OXIDASE TYPE B

  1981cited by this paper
• Some puzzling pharmacological effects of monoamine oxidase inhibitors.

  1972cited by this paper

• The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson's Disease - An Update.

  2021cites this paper
• Possible neuroprotective effects of rasagiline in Alzheimer’s disease: a SPECT study

  2020cites this paper
• Other Compounds From Tobacco With Potential Impact on Neurodegenerative Diseases

  2018cites this paper
• Advances in Drug Development for Parkinson's Disease: Present Status

  2014cites this paper
• [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].

  2013cites this paper
• Rasagilina en monoterapia en pacientes en fases tempranas de la enfermedad de Parkinson y en terapia combinada y coadyuvante a levodopa en fases moderada y avanzada

  2013cites this paper
• Multi Target Neuroprotective and Neurorestorative Anti-Parkinson and Anti-Alzheimer Drugs Ladostigil and M30 Derived from Rasagiline

  2013influential citation
• Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms

  2013cites this paper
• Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.

  2013cites this paper
• Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature

  2013cites this paper
• Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders

  2013cites this paper
• Adjunctive therapy in Parkinson’s disease: the role of rasagiline

  2012cites this paper
• Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.

  2012cites this paper
• Rasagiline

  2012cites this paper
• Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.

  2011cites this paper
• Multifunctional neuroprotective derivatives of rasagiline as anti-alzheimer’s disease drugs

  2011cites this paper
• Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases.

  2011cites this paper
• Disease Modification in Parkinson’s Disease

  2011cites this paper
• MAO-inhibitors in Parkinson's Disease

  2011cites this paper
• Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.

  2010cites this paper
• Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.

  2010cites this paper
• [Rasagiline: effectiveness and protection in Parkinson's disease].

  2010cites this paper
• Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

  2009cites this paper
• Rasagiline for the management of Parkinson’s disease

  2008cites this paper
• Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.

  2008cites this paper
• Multifunctional neuroprotective–neurorescue drugs for Parkinson’s disease

  2007cites this paper
• Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.

  2007cites this paper
• Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?

  2007cites this paper
• Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?

  2007cites this paper
• Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil

  2007cites this paper
• Rasagiline Promotes Regeneration of Substantia Nigra Dopaminergic Neurons in Post-MPTP-induced Parkinsonism via Activation of Tyrosine Kinase Receptor Signaling Pathway

  2007cites this paper
• Advances in the Pharmacologic Management of Early Parkinson Disease

  2007cites this paper
• Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.

  2007cites this paper
• Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil

  2006cites this paper
• Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety.

  2006cites this paper
• Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.

  2006cites this paper
• Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?

  2006cites this paper
• Clinical trials with rasagiline

  2006cites this paper
• Rasagiline in the pharmacotherapy of Parkinson’s disease – a review

  2005cites this paper
• Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells.

  2005cites this paper
• Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: Effects of simultaneously administered nomifensine, deprenyl, and 1-t-butyl-4,4-diphenylpiperidine

  2005cites this paper
• Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease

  2005influential citation
• Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.

  2005cites this paper
• Recent advances in Parkinson’s disease therapy: use of monoamine oxidase inhibitors

  2005cites this paper
• Chapter V Motor function(s) of the nigrostriatal dopamine system: Studies of lesions and behavior

  2005cites this paper
• The Molecular Mechanism of the Neuroprotective Action of Antioxidants Compared with the Anti-Parkinson Drug, Rasagiline

  2005cites this paper
• Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.

  2005cites this paper
• Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor

  2004cites this paper
• A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

  2004cites this paper
• Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax.

  2004cites this paper
• Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax.

  2004cites this paper
• Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

  2004cites this paper
• Synthesis and Initial Results for MAO-B Inhibition by New N-Propargyl-3-pyrrol-1-ylindanamine Derivatives, Analogues of Rasagiline

  2003cites this paper
• A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.

  2003cites this paper
• The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.

  2003cites this paper
• Attenuation of MPTP‐induced dopaminergic neurotoxicity by TV3326, a cholinesterase‐monoamine oxidase inhibitor

  2003cites this paper
• Rasagiline: an anti-Parkinson drug with neuroprotective activity

  2003cites this paper
• Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline.

  2002cites this paper
• The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells

  2002cites this paper
• A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

  2002cites this paper
• Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

  2001cites this paper
• The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo

  2001cites this paper
• Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco.

  2001cites this paper
• Molecular Basis of Neuroprotective Activities of Rasagiline and the Anti-Alzheimer Drug TV3326 [lpar;N-Propargyl-(3R) Aminoindan-5-YL)-Ethyl Methyl Carbamate]

  2001cites this paper
• Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders.

  1998cites this paper
• Использование r-энантиомера n-пропаргил-1-аминоиндана, его солей и композиции, содержащие их

  1996cites this paper
• Monoamine Oxidase B Inhibitors

  1996cites this paper
• Using n-propargyl-1-aminoindane r-enantiomer, its salts and compositions comprising thereof

  1996cites this paper
• Pharmacological actions of l‐deprenyl (selegiline) and other selective monoamine oxidase B inhibitors *

  1994cites this paper
• Medicinal Chemistry of Present and Future MAO-B Inhibitors

  1993cites this paper
• The new generation of monoamine oxidase inhibitors.

  1992cites this paper
• Interactions Between MPTP-Induced and Age-Related Neuronal Death in a Murine Model of Parkinson’s Disease

  1992cites this paper
• Drug disposition in the mammalian eye and brain: a comparison of mechanisms.

  1991cites this paper
• Characterization of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) binding sites in C57BL/6 mouse brain: mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites.

  1991cites this paper
• Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1989cites this paper
• Deprenyl as prophylaxis against Parkinson's disease?

  1988cites this paper
• Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse.

  1987cites this paper
• [72] Assay and purification of liver monoamine oxidase

  1987cites this paper
• Suppression of mating behaviour in the male rat by intracerebroventricular infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1987cites this paper
• Assay and purification of liver monoamine oxidase.

  1987cites this paper
• The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (mptp) and its relevance to parkinson's disease.

  1987cites this paper
• Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.

  1986cites this paper
• Prevention of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic toxicity in mice by MDL 72145, a selective inhibitor of MAO-B.

  1986cites this paper
• Synthetic Heroin-Induced Parkinsonism

  1986cites this paper